This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelly, K. Articles by Bunn, P. A. Search for Related Content PubMed PubMed Citation Articles by Kelly, K. Articles by Bunn, P. A., Jr.

A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer¹

Division of Medical Oncology and the Lung Cancer Program [K. K., M. E. W., P. A. B.] and Department of Preventive Medicine and Biostatistics [Z. P., J. M.], University of Colorado Cancer Center, Denver, Colorado 80262

This Phase I study was designed to determine the maximally tolerated dose (MTD) of paclitaxel with standard doses of cisplatin and etoposide for patients with untreated extensive stage small cell lung cancer (SCLC). Secondary objectives were to determine the toxicities, response rate, response duration, and overall survival in this cohort. Twenty-eight SCLC patients were enrolled into four dose levels. All patients received a fixed dose of cisplatin at 80 mg/m², i.v., day 1. The first group received etoposide 50 mg/m², i.v. day 1 and 100 mg/m² p.o., days 2–3, whereas all subsequent groups received etoposide 80 mg/m², i.v., day 1 and 160 mg/m², p.o., days 2–3. The paclitaxel starting dose was 135 mg/m², i.v., over a 3-h period and was escalated to 175 and 200 mg/m². Cycles were repeated every 21 days for a maximum of six cycles. Granulocyte-colony stimulating factor was not given prophylactically but was allowed in subsequent cycles according to the American Society of Clinical Oncologists guidelines. All 28 SCLC patients were evaluable for toxicity, and 23 patients were evaluable for response. Myelosuppression was the major toxicity, with grade 4 neutropenia occurring in 23 of 28 patients (82%), but febrile neutropenia was uncommon and developed in 4 patients (14%). Grade 4 thrombocytopenia and anemia were rare, occurring as isolated events in one patient each. Dose-limiting peripheral neuropathy was observed at a paclitaxel dose of 200 mg/m². Grade 4 nausea/vomiting and diarrhea were also noted at this dose level. Five patients had complete responses (22%), and 14 patients had partial responses (61%). The overall response rate was 83% with a median time to progression of 7.5 months, a median survival of 10 months, and a 1-year survival rate of 39%. This three-drug combination of paclitaxel with cisplatin and etoposide is active with acceptable toxicity. Neurotoxicity was dose limiting at 200 mg/m² of paclitaxel. Neutropenia was frequent but not associated with significant morbidity. The recommended doses for future clinical trials are 175 mg/m² paclitaxel, i.v., over a 3-h period on day 1 with 80 mg/m² cisplatin, i.v., on day 1 and 80 mg/m² etoposide, i.v., on day 1 and 160 mg/m² p.o. on days 2 and 3 with growth factor support. The Southwestern Oncology Group has instituted a Phase II study with this dose schedule.

This article has been cited by other articles:

				G. R. Simon and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 324S - 339S. [Abstract] [Full Text] [PDF]

				H. B. Niell, J. E. Herndon II, A. A. Miller, D. M. Watson, A. B. Sandler, K. Kelly, R. S. Marks, M. C. Perry, R. H. Ansari, G. Otterson, et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 J. Clin. Oncol., June 1, 2005; 23(16): 3752 - 3759. [Abstract] [Full Text] [PDF]

				J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				K. Kelly, L. Lovato, P. A. Bunn Jr., R. B. Livingston, J. Zangmeister, S. A. Taylor, D. Roychowdhury, J. J. Crowley, and D. R. Gandara Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group Clin. Cancer Res., August 1, 2001; 7(8): 2325 - 2329. [Abstract] [Full Text] [PDF]